CR20210474A - Compuestos de neuregulina-4 y métodos de uso - Google Patents

Compuestos de neuregulina-4 y métodos de uso

Info

Publication number
CR20210474A
CR20210474A CR20210474A CR20210474A CR20210474A CR 20210474 A CR20210474 A CR 20210474A CR 20210474 A CR20210474 A CR 20210474A CR 20210474 A CR20210474 A CR 20210474A CR 20210474 A CR20210474 A CR 20210474A
Authority
CR
Costa Rica
Prior art keywords
compounds
neuregulin
methods
nrg4
nrg
Prior art date
Application number
CR20210474A
Other languages
English (en)
Inventor
Josef George Heuer
Wei Ni
Avinash Muppidi
Jonathan Wesley Day
James David Pancook
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20210474A publication Critical patent/CR20210474A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a compuestos de neuregulina (NRG) 4 y métodos de tratamiento con compuestos NRG4.
CR20210474A 2019-04-01 2020-03-31 Compuestos de neuregulina-4 y métodos de uso CR20210474A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962827386P 2019-04-01 2019-04-01
PCT/US2020/025921 WO2020205840A1 (en) 2019-04-01 2020-03-31 Neuregulin-4 compounds and methods of use

Publications (1)

Publication Number Publication Date
CR20210474A true CR20210474A (es) 2021-10-13

Family

ID=70465394

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210474A CR20210474A (es) 2019-04-01 2020-03-31 Compuestos de neuregulina-4 y métodos de uso

Country Status (25)

Country Link
US (3) US11242370B2 (es)
EP (1) EP3947428A1 (es)
JP (1) JP7036953B2 (es)
KR (1) KR102717638B1 (es)
CN (1) CN113677699B (es)
AR (1) AR121035A1 (es)
AU (1) AU2020252184B2 (es)
BR (1) BR112021017670A2 (es)
CA (2) CA3223554A1 (es)
CL (1) CL2021002455A1 (es)
CO (1) CO2021012807A2 (es)
CR (1) CR20210474A (es)
DO (1) DOP2021000194A (es)
EA (1) EA202192288A1 (es)
EC (1) ECSP21072840A (es)
IL (1) IL286697A (es)
JO (1) JOP20210264A1 (es)
MA (1) MA55532A (es)
MX (1) MX2021011983A (es)
PE (1) PE20212326A1 (es)
PH (1) PH12021552427A1 (es)
SG (1) SG11202110484VA (es)
TW (1) TWI787596B (es)
WO (1) WO2020205840A1 (es)
ZA (2) ZA202106570B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3355909B1 (en) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
WO2023150693A2 (en) * 2022-02-03 2023-08-10 Avexegen Therapeutics, Inc. Neuregulin-4 analogs and methods of using thereof in disease treatment
WO2023230491A1 (en) 2022-05-25 2023-11-30 Eli Lilly And Company Methods of using neuregulin-4 compounds
EP4572788A2 (en) * 2022-08-15 2025-06-25 The Regents of The University of Michigan Methods and compositions for treating cancer
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
JP2001519400A (ja) 1997-10-14 2001-10-23 ケンブリッジ ニューロサイエンス インク． ニューレグリン使用を含む治療法
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
WO2001014415A2 (en) 1999-08-20 2001-03-01 Chiron Corporation Egfh2 genes and gene products
US7094882B2 (en) * 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US6544759B1 (en) * 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
IL153052A0 (en) 2000-05-23 2003-06-24 Cenes Pharmaceuticals Inc Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
JP2005508887A (ja) 2001-08-03 2005-04-07 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション Ｅｇｆ受容体の結晶構造に基づいたスクリーニング方法
WO2003025142A2 (en) 2001-09-16 2003-03-27 Nuvelo, Inc. Novel nucleic acids and secreted polypeptides
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
CN1498656A (zh) * 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
AU2004265512B2 (en) * 2003-08-19 2010-12-16 Yeda Research And Development Co Ltd Splice variants of ErbB ligands, compositions and uses thereof
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
JP5738516B2 (ja) 2005-12-30 2015-06-24 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド 心機能改善のためのニューレグリンの徐放
BRPI0713272A2 (pt) * 2006-06-12 2017-05-02 Receptor Biologix Inc produtos terapêuticos específicos ao receptor na superfície de pan-células
ES2315110B1 (es) 2006-07-14 2009-12-30 Universidad De Barcelona Compuestos para el tratamiento de enfermedades relacionadas con la resistencia a la insulina.
CN103432681A (zh) * 2007-05-25 2013-12-11 上海泽生科技开发有限公司 包含神经调节蛋白的药物制剂及装置
CN101310779A (zh) * 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
CN101397337A (zh) * 2007-09-25 2009-04-01 上海泽生科技开发有限公司 神经调节蛋白突变体及其用途
CN102159236A (zh) 2008-07-17 2011-08-17 阿索尔达治疗公司 用于治疗或预防心力衰竭的神经调节蛋白或其亚序列的治疗性施剂
EP2328606B1 (en) 2008-08-15 2016-10-05 Acorda Therapeutics, Inc. Compositions and methods for treatment during non-acute periods following cns neurological injury
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
JP2012509908A (ja) 2008-11-28 2012-04-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
EP3087998B1 (en) 2009-06-09 2019-09-04 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin based methods for treating heart failure
WO2011006072A2 (en) 2009-07-10 2011-01-13 Northwestern University Cardioprotective role of hepatic cells and hepatocyte secretory factors in myocardial ischemia
WO2011011388A2 (en) 2009-07-22 2011-01-27 Children's Medical Center Corporation Neuregulin induced regeneraton of heart muscle muscle
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
US9029328B2 (en) 2010-03-24 2015-05-12 The Brigham And Women's Hospital, Inc. Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
WO2013025817A1 (en) 2011-08-15 2013-02-21 Children's Hospital Los Angeles Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2014051567A1 (en) 2012-09-26 2014-04-03 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
US8748131B2 (en) 2012-09-26 2014-06-10 Morehouse School Of Medicine Chimeric neuregulins and method of making and use thereof
US10894815B2 (en) 2012-10-08 2021-01-19 Zensun (Shanghai) Science & Technology, Co., Ltd. Compositions and methods for treating heart failure in diabetic patients
EP2964249A1 (en) 2013-03-06 2016-01-13 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
EP2976094B1 (en) 2013-03-21 2019-08-28 The Regents of The University of Michigan Methods of treating metabolic disorders
RU2015154737A (ru) 2013-05-22 2017-06-27 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи, Ко., Лтд. Пролонгированное высвобождение нейрегулина для лечения сердечной недостаточности
CN104211799B (zh) 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
US9352923B2 (en) 2014-02-26 2016-05-31 Eastman Kodak Company Air shoe with roller providing lateral constraint
EP3131570A1 (en) 2014-04-15 2017-02-22 Universiteit Antwerpen Treatment of nephropathy
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) * 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3247380A1 (en) 2015-01-20 2017-11-29 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
US10017574B2 (en) 2015-05-07 2018-07-10 Yeda Research And Development Co. Ltd. Methods, kits and devices for promoting cardiac regeneration
EP3355909B1 (en) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
PE20210111A1 (es) 2018-04-11 2021-01-19 Salubris Biotherapeutics Inc Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
AR121035A1 (es) * 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso

Also Published As

Publication number Publication date
CO2021012807A2 (es) 2021-10-29
ZA202304093B (en) 2024-09-25
EA202192288A1 (ru) 2022-01-21
CN113677699A (zh) 2021-11-19
US12145972B2 (en) 2024-11-19
CL2021002455A1 (es) 2022-05-27
DOP2021000194A (es) 2021-10-31
CN113677699B (zh) 2024-06-11
BR112021017670A2 (pt) 2021-11-16
AR121035A1 (es) 2022-04-13
AU2020252184B2 (en) 2022-12-08
US20250092107A1 (en) 2025-03-20
MX2021011983A (es) 2021-11-03
JP7036953B2 (ja) 2022-03-15
AU2020252184A1 (en) 2021-10-14
US11242370B2 (en) 2022-02-08
JOP20210264A1 (ar) 2023-01-30
PE20212326A1 (es) 2021-12-14
IL286697A (en) 2021-10-31
PH12021552427A1 (en) 2022-07-11
US20200354421A1 (en) 2020-11-12
ZA202106570B (en) 2025-01-29
SG11202110484VA (en) 2021-10-28
MA55532A (fr) 2022-02-09
JP2021522314A (ja) 2021-08-30
WO2020205840A1 (en) 2020-10-08
CA3223554A1 (en) 2020-10-08
ECSP21072840A (es) 2021-11-18
TW202104251A (zh) 2021-02-01
EP3947428A1 (en) 2022-02-09
KR20210134699A (ko) 2021-11-10
US20220112255A1 (en) 2022-04-14
KR102717638B1 (ko) 2024-10-16
TWI787596B (zh) 2022-12-21
CA3132135A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
ZA202304093B (en) Neuregulin-4 compounds and methods of use
MX2022009369A (es) Compuestos y usos de estos.
MX2023005436A (es) Compuestos y usos de estos.
MX2022009308A (es) Compuestos y usos de estos.
ZA202207804B (en) Compounds and uses thereof
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
ZA202208421B (en) Compounds and uses thereof
PH12022551522A1 (en) Smarca degraders and uses thereof
MX2021012659A (es) Composiciones de seda para el cuidado del cabello.
SA522431538B1 (ar) طُرق وتركيبات لعلاج تساقط الشعر
MX2025003294A (es) Moduladores de la expresion de apol1
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
PH12021552588A1 (en) Cd73 inhibitors
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2020006191A (es) Bacteriocinas terapeuticas.
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
PH12022550118A1 (en) Enzyme inhibitors
MX2021001877A (es) Composiciones y métodos para el tratamiento de lesión pulmonar aguda.
MX2022003816A (es) Compuestos antibacterianos.
MX2022003814A (es) Compuestos antibacterianos de 4-quinolinona.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
WO2020185651A3 (en) Compositions and methods for treating huntington's disease
WO2020032902A3 (en) Aksolotl blastema for use in the treatment of wounds and burns
HK40081493A (en) Compositions and methods regulating folliculogenesis for the treatment of ovarian senescence
EA202092204A1 (ru) Композиции